Maxim Group analyst Jason McCarthy has maintained their neutral stance on DARE stock, giving a Hold rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jason McCarthy has given his Hold rating due to a combination of factors related to Daré Bioscience’s current financial and developmental status. The company has made progress with its Ovaprene product, showing positive interim results in its Phase 3 study, which indicates a promising safety and effectiveness profile. However, despite these advancements, Daré Bioscience faces financial challenges that could impact its future operations.
While the company has secured some grant funding and has potential capital from its equity line, it still requires additional funding to support its ongoing projects, such as the P3 program for topical sildenafil. This need for further capital could lead to significant dilution for current shareholders. Therefore, given the balance of positive product development against financial uncertainties, McCarthy has opted to maintain a Hold rating on the stock.
In another report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $3.00 price target.
DARE’s price has also changed moderately for the past six months – from $3.330 to $2.840, which is a -14.71% drop .